Skip to main content
SpringerLink
Log in

Raltitrexed: a convenient alternative for advanced colorectal cancer

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wingo P, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995 Jan/Feb; 45(1): 8–30

    Article  PubMed  CAS  Google Scholar 

  2. Estève J, Kricker A, Ferlay J, et al. Facts and figures of cancer in the European Community. Lyon: International Agency for Research on Cancer, 1993

    Google Scholar 

  3. Boring CC, Squires TS, Tong T, et al. Cancer statistics, 1994. CA Cancer J Clin 1994 Jan/Feb; 44(1): 7–26

    Article  PubMed  CAS  Google Scholar 

  4. van Triest B, van Groeningen CJ, Pinedo HM. Current chemotherapeutic possibilities in the treatment of colorectal cancer. Eur J Cancer A 1995 Jul-Aug; 31 A: 1193–7

    Article  PubMed  Google Scholar 

  5. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752–5

    Article  PubMed  CAS  Google Scholar 

  6. Gunasekara NS, Faulds D. Raltitrexed: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1998 Mar; 55(3): 423–35

    Article  PubMed  CAS  Google Scholar 

  7. Zeneca Pharma. Tomudex. In: ABPI compendium of data sheets and summaries of product characteristics. London: Datapharm Publications Limited, 1996-97: 1307–9

    Google Scholar 

  8. Faulding Pharmaceuticals plc. Fluorouracil injection BP. In: ABPI compendium of data sheets and summaries of product characteristics. London: Datapharm Publications Limited, 1996-97: 336–7

    Google Scholar 

  9. Cambridge Laboratories. Fluorouracil. In: ABPI compendium of data sheets and summaries of product characteristics. London: Datapharm Publications Limited, 1996-97: 185–6

    Google Scholar 

  10. Irinotecan hydrochloride. In: PDR Generics. 4th ed. Montvale: Medical Economics Company, 1998: 1598–601

    Google Scholar 

  11. Wiseman LR, Markham A. Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996 Oct; 52(4): 606–23

    Article  PubMed  CAS  Google Scholar 

  12. Zalcberg J. Overview of the tolerability of ‘Tomudex’ (raltitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997; 8 Suppl. 2: S17–22

    Article  PubMed  CAS  Google Scholar 

  13. Ross P, Heron J, Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer A 1996; 32A Suppl. 5: S13–7

    Article  PubMed  Google Scholar 

  14. Summerhayes M, Wanklyn SJ, Shakespeare RA, et al. Reduced pharmacy resource utilization associated with raltitrexed treatment of advanced colorectal cancer. J Oncol Pharm Practice 1997; 3(1): 24–30

    Article  Google Scholar 

  15. Elliott R. An analysis of drug costs for the management of chemotherapy-related side effects in advanced colorectal cancer. J Oncol Pharm Practice 1996; 2(3): 186–90

    Article  Google Scholar 

  16. Van Cutsem E. Future developments with ‘Tomudex’ (raltitrexed). Anticancer Drugs 1997; 8 Suppl. 2: S33–8

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raltitrexed: a convenient alternative for advanced colorectal cancer. Drugs Ther. Perspect 12, 1–5 (1998). https://doi.org/10.2165/00042310-199812040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199812040-00001

Search

Navigation